实用癌症杂志
實用癌癥雜誌
실용암증잡지
The Practical Journal of Cancer
2015年
8期
1200-1202
,共3页
赛福丁·克尤木%布力布·吉力斯汉%唐勇
賽福丁·剋尤木%佈力佈·吉力斯漢%唐勇
새복정·극우목%포력포·길력사한%당용
贝伐单抗%FOLFOX-6方案%转移性结肠癌%临床疗效
貝伐單抗%FOLFOX-6方案%轉移性結腸癌%臨床療效
패벌단항%FOLFOX-6방안%전이성결장암%림상료효
Bevacizumab%FOLFOX-6 regimen%Metastatic colorectal cancer%Clinical efficacy
目的 探讨FOLFOX-6化疗方案联合贝伐单抗靶向治疗转移性结肠癌的临床疗效. 方法 选择转移性结肠癌患者50例,随机分为观察组和对照组,每组各25例. 对照组采用FOLFOX-6化疗方案,观察组采用贝伐珠单抗联合FOLFOX-6化疗方案治疗. 对两组患者治疗后的近期疗效、不良反应及生存率进行比较. 结果 观察组患者的临床获益率(88.0%)明显高于对照组(76.0%),具有显著性差异(P<0.05). 观察组患者白细胞减少、血小板减少、恶心呕吐及腹泻发生率与对照组比较,无显著性差异(P>0.05). 观察组患者6个月生存率和1年生存率均明显高于对照组,具有显著性差异(P<0.05). 结论 FOLFOX-6化疗方案联合贝伐单抗靶向治疗转移性结肠癌,可明显提高近期疗效和患者生存率,值得临床推广与应用.
目的 探討FOLFOX-6化療方案聯閤貝伐單抗靶嚮治療轉移性結腸癌的臨床療效. 方法 選擇轉移性結腸癌患者50例,隨機分為觀察組和對照組,每組各25例. 對照組採用FOLFOX-6化療方案,觀察組採用貝伐珠單抗聯閤FOLFOX-6化療方案治療. 對兩組患者治療後的近期療效、不良反應及生存率進行比較. 結果 觀察組患者的臨床穫益率(88.0%)明顯高于對照組(76.0%),具有顯著性差異(P<0.05). 觀察組患者白細胞減少、血小闆減少、噁心嘔吐及腹瀉髮生率與對照組比較,無顯著性差異(P>0.05). 觀察組患者6箇月生存率和1年生存率均明顯高于對照組,具有顯著性差異(P<0.05). 結論 FOLFOX-6化療方案聯閤貝伐單抗靶嚮治療轉移性結腸癌,可明顯提高近期療效和患者生存率,值得臨床推廣與應用.
목적 탐토FOLFOX-6화료방안연합패벌단항파향치료전이성결장암적림상료효. 방법 선택전이성결장암환자50례,수궤분위관찰조화대조조,매조각25례. 대조조채용FOLFOX-6화료방안,관찰조채용패벌주단항연합FOLFOX-6화료방안치료. 대량조환자치료후적근기료효、불량반응급생존솔진행비교. 결과 관찰조환자적림상획익솔(88.0%)명현고우대조조(76.0%),구유현저성차이(P<0.05). 관찰조환자백세포감소、혈소판감소、악심구토급복사발생솔여대조조비교,무현저성차이(P>0.05). 관찰조환자6개월생존솔화1년생존솔균명현고우대조조,구유현저성차이(P<0.05). 결론 FOLFOX-6화료방안연합패벌단항파향치료전이성결장암,가명현제고근기료효화환자생존솔,치득림상추엄여응용.
Objective To explore clinical efficacy of FOLFOX-6 regimen combined with bevacizumab in the treatment of patients with metastatic colorectal cancer.Methods Totally 50 cases of metastatic colorectal cancer patients were randomly di-vided into the observation group and the control group,with 25 cases in each group.The control group was treated by FOLFOX-6 regimen,while the observation group was treated by bevacizumab combined with FOLFOX-6 regimen.The short-term curative effect,adverse reactions and survival rates between the 2 groups were compared.Results The clinical benefit rate in the obser-vation group(88.0%) was higher than that of the control group (76.0%) (P<0.05).There had no statistical significance in the incidence of leukopenia,thrombocytopenia,nausea and vomiting and diarrhea between the 2 groups (P>0.05).6-month sur-vival rate and 1-year survival rate in the observation group were higher than those of the control group ( P<0.05) .Conclusion FOLFOX-6 regimen combined with bevacizumab in the treatment of metastatic colorectal cancer can enhance the short-term cura-tive effect and survival rate.It is worthy of further clinical popularization.
